GlassScriptPhysician profile
William Patrick Mcdonough
NPI 1124647573
$2,782.18
in general payments reported to CMS, 2019-2025
16 companies · $1,223 in 2025
The $1,223 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $74.39 · 2022: $28.63 · 2023: $282 · 2024: $1,174 · 2025: $1,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,679.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $445.88 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $425.70 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $330.56 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $296.59 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $269.46 | 2023-2025 | |
| Pfizer INC. | $265.91 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.42 | 2023-2025 | Jardiance |
| Exact Sciences Corporation | $145.24 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $75.32 | 2024-2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $64.62 | 2025 | Inspire |
| Mylan Specialty L.P. | $63.01 | 2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.91 | 2024-2025 | Xifaxan, Trulance |
| Amgen INC. | $43.25 | 2025 | Repatha, Otezla |
| Ibsa Pharma INC. | $38.64 | 2025 | Tirosint, Licart, Flector |
| Esperion Therapeutics, INC. | $29.84 | 2024-2025 | Nexletol |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $26.83 | 2024 | Contrave, Onzetra Xsail |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mcdonough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.